SCHEMBL6503827

SCHEMBL6503827

O=C(Nc1ccc(NCCc2ccccn2)cc1)C1=C(c2ccc(F)cc2)CCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.50
▸ CTNNB1 P35222 1/20 0.46
▸ TCF7L2 Q9NQB0 1/20 0.46
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ NAMPT P43490 3/20 0.44
▸ CNR1 P21554 1/20 0.43
▸ RAB9A P51151 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ PDE10A Q9Y233 1/20 0.42
▸ HPGD P15428 1/20 0.41
▸ DPP7 Q9UHL4 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ TAS1R3 Q7RTX0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489289 0.91 L3MBTL1 (0.46) HTTCTNNB1TCF7L2MEN1KMT2A
SCHEMBL6501992 0.91 CNR1 (0.54) CTNNB1TCF7L2MEN1KMT2AKDM4E
SCHEMBL6490864 0.90 L3MBTL1 (0.45) HTTCTNNB1TCF7L2MEN1KMT2A
SCHEMBL6491912 0.90 RAB9A (0.48) HTTCTNNB1TCF7L2MEN1KMT2A
SCHEMBL6493547 0.90 L3MBTL1 (0.45) HTTCTNNB1TCF7L2MEN1KMT2A
SCHEMBL6490871 0.90 L3MBTL1 (0.45) HTTCTNNB1TCF7L2MEN1KMT2A
SCHEMBL6487662 0.89 TRPV1 (0.49) NAMPT
SCHEMBL6487298 0.89 L3MBTL1 (0.46) HTTCTNNB1TCF7L2MEN1KMT2A
SCHEMBL6490340 0.89 MAOA (0.47) HTTCTNNB1TCF7L2MEN1KMT2A
SCHEMBL6499824 0.89 RAB9A (0.60) MEN1KMT2AMAPTKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 — — US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 — — EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 HTT 2574/4885CTNNB1 1793/4885TCF7L2 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback